ArticleMolecular imaging and biology2010
Dual in vivo quantification of integrin-targeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT).
Article in Molecular imaging and biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 79 citations in OpenAlex.
- Article
- Bone marrow endothelial dysfunction promotes myeloid cell expansion in cardiovascular disease.Nature cardiovascular research · 2022Article
- Depth-recognizable time-domain fluorescence molecular tomography in reflective geometry.Biomedical optics express · 2021Article
- In Vivo Evaluation of a Miniaturized Fluorescence Molecular Tomography (FMT) Endoscope for Breast Cancer Detection Using Targeted Nanoprobes.International journal of molecular sciences · 2020Article
- Paradigms in Fluorescence Molecular Imaging: Maximizing Measurement of Biological Changes in Disease, Therapeutic Efficacy, and Toxicology/Safety.Molecular imaging and biology · 2019Review
- Oral and Subcutaneous Administration of a Near-Infrared Fluorescent Molecular Imaging Agent Detects Inflammation in a Mouse Model of Rheumatoid Arthritis.Scientific reports · 2019Article
- A thermo-sensitive fluorescent agent based method for excitation light leakage rejection for fluorescence molecular tomography.Physics in medicine and biology · 2019Article
- Full density fluorescence molecular tomography (FD-FMT) based on a dichroic mirror.Applied optics · 2018Article
- OpticalOncotarget · 2018Article
- Oral Administration and Detection of a Near-Infrared Molecular Imaging Agent in an Orthotopic Mouse Model for Breast Cancer Screening.Molecular pharmaceutics · 2018Article
- Early Detection of Acute Drug-Induced Liver Injury in Mice by Noninvasive Near-Infrared Fluorescence Imaging.The Journal of pharmacology and experimental therapeutics · 2017Article
- Imaging the Tumor Microenvironment.Advances in experimental medicine and biology · 2017Review
- Luminescent Probe Based Techniques for Hypoxia Imaging.Journal of nanomedicine research · 2017Article
- Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer.Scientific reports · 2016Article
- Near-Infrared Optical Imaging Noninvasively Detects Acutely Damaged Muscle.The American journal of pathology · 2016Article
- Optical imaging probes in oncology.Oncotarget · 2016Review
- Tumor Targeting and Pharmacokinetics of a Near-Infrared Fluorescent-Labeled δ-Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5.Molecular pharmaceutics · 2016Article
- Orally active αvβ3 integrin inhibitor MK-0429 reduces melanoma metastasis.Oncology reports · 2015Article
- Improved sparse reconstruction for fluorescence molecular tomography with L1/2 regularization.Biomedical optics express · 2015Article
- Advances in optical imaging for pharmacological studies.Frontiers in pharmacology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIntegrins, especially α(v)β(3) and α(v)β(5), are upregulated in tumor cells and activated endothelial cells and as such, serve as cancer biomarkers. We developed a novel near-infrared-labeled optical agent for the in vivo detection and quantification of α(v)β(3)/α(v)β(5). PROCEDURES: A small peptidomimetic α(v)β(3) antagonist was synthesized, coupled to a near-infrared fluorescent (NIRF) dye, and tested for binding specificity using integrin-overexpressing cells, inhibition of vitronectin-mediated cell attachment, binding to tumor and endothelial cells in vitro, and competition studies. Pharmacokinetics, biodistribution, specificity of tumor targeting, and the effect of an antiangiogenic treatment were assessed in vivo.
resultsThe integrin NIRF agent showed strong selectivity towards α(v)β(3/)α(v)β(5) in vitro and predominant tumor distribution in vivo, allowing noninvasive and real-time quantification of integrin signal in tumors. Antiangiogenic treatment significantly inhibited integrin signal in vivo but had no effect on a cathepsin-cleavable NIR agent. Simultaneous imaging revealed different patterns of distribution reflecting the underlying differences in integrin and cathepsin biology during tumor progression.
conclusionsNIRF-labeled integrin antagonists allow noninvasive molecular fluorescent imaging and quantification of tumors in vivo, improving and providing more refined approaches for cancer detection and treatment monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.